ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
Uncoupling Type I Interferon Benefits From Inflammatory Toxicity: Transformer-Prioritized Precision Agonists for Potent and Safer Cancer Immunotherapy.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Uncoupling Type I Interferon Benefits From Inflammatory Toxicity: Transformer-Prioritized Precision Agonists for Potent and Safer Cancer Immunotherapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Paclitaxel (PTX) chemotherapy is constrained by an "immunomodulatory paradox," where antitumor Type I Interferon (IFN-I) activation is coupled with detrimental pro-inflammatory cascades. To address this challenge, we developed Deep Learning for Innate Immunity Modulatory Potential (DLINP), a Transformer-based framework designed to identify precision immunomodulators that uncouple IFN-I induction from deleterious inflammatory signaling. Screening 123 million entities identified Co68-an organometallic PNP-pincer complex-as a dual-functional agent with superior potency to conventional taxanes. In pancreatic ductal adenocarcinoma (PDAC) models, Co68 elicited robust antitumor responses that exceeded those of the gold-standard STING agonist DMXAA. Single-cell and spatial transcriptomics revealed that Co68 selectively re-engineered the myeloid compartment, reprogramming tumor-associated macrophages toward an interferon-stimulated gene (ISG)-high phenotype while quenching the pro-inflammatory IL1β-PGE2 feedback loop. This reconfiguration converted "cold" tumor microenvironments into "hot" landscapes, enhancing NK and CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.